Nexalin Technology, Inc. (NXL) vs Revelation Biosciences, Inc. (REVB)
A side-by-side comparison of Nexalin Technology, Inc. and Revelation Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NXL
Nexalin Technology, Inc.
$4.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
REVB
Revelation Biosciences, Inc.
$0.75HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — NXL vs REVB
growth of $100 · dividends reinvested · last 4yNXL -92.0% (-46.7%/yr)REVB -100.0% (-94.4%/yr)NXL compounded faster over this window
Log scale — wide-divergence pair
NXL REVB
NXL vs REVB: by the numbers
- •NXL is the larger company ($3M vs $3M market cap).
- •Both run net losses; REVB's is the smaller (0.00% vs -4139.38% net margin).
Metrics side by side
Valuation
| Metric | NXL | REVB |
|---|---|---|
| P/S ratio | 15.20 | N/A |
| P/B ratio | 2.17 | 0.29 |
Profitability
| Metric | NXL | REVB |
|---|---|---|
| Gross margin | 79.65% | 0.00% |
| Operating margin | -2781.69% | 0.00% |
| Net margin | -4139.38% | 0.00% |
| ROE | -591.60% | -106.79% |
| ROIC | -600.62% | -104.28% |
Growth (annualized)
| Metric | NXL | REVB |
|---|---|---|
| Revenue CAGR (5Y) | 10.22% | N/A |
| Total return CAGR (5Y) | N/A | -93.52% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.